The International Myeloma Working Group (IMWG) recommends that whole-body imaging should be done in all patients with suspected MM and in MGUS patients with high risks, which include an M-protein of 1.5 g/dl or more and an abnormal free light chain ratio with non-IgM MGUS (19). This evidence concerns the gene MYOM2 and Miyoshi myopathy.